Treatment of prostate cancer cells with Wnt3A CM or purified recombinant Wnt3A protein significantly enhanced cell growth and migration [31], [32], while treatment of prostate cancer cells with the LRP6 antagonist Dkk1 significantly inhibited cell growth and migration [32]. Here, DKK1 is linked to prostate cancer.